Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
about
A2058Malme-3MSK-MEL-1SK-MEL-100SK-MEL-103SK-MEL-105SK-MEL-109SK-MEL-11SK-MEL-110SK-MEL-113SK-MEL-117SK-MEL-118SK-MEL-119SK-MEL-12SK-MEL-127SK-MEL-13SK-MEL-130SK-MEL-131SK-MEL-133SK-MEL-146SK-MEL-147SK-MEL-15SK-MEL-153SK-MEL-161SK-MEL-170SK-MEL-173SK-MEL-174SK-MEL-176SK-MEL-178SK-MEL-181SK-MEL-182SK-MEL-186SK-MEL-187SK-MEL-188SK-MEL-19SK-MEL-190SK-MEL-191SK-MEL-192SK-MEL-196SK-MEL-197
P1343
MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapyMultiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic TargetsMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateA RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressorBeyond BRAF: where next for melanoma therapy?KRAS as a Therapeutic TargetCIViC databaseEffect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.Negative feedback regulation of the ERK1/2 MAPK pathwayA novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent mannerFunction and Clinical Implications of Long Non-Coding RNAs in Melanoma.Synthetic lethality: emerging targets and opportunities in melanoma.Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.The NF1 somatic mutational landscape in sporadic human cancers.The MAPK pathway as an apoptosis enhancer in melanoma.NF1 regulation of RAS/ERK signaling is required for appropriate granule neuron progenitor expansion and migration in cerebellar development.BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Genomic Classification of Cutaneous MelanomaOvercoming resistance to BRAF inhibition in BRAF-mutated metastatic melanomaPrenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cellsActivating MET kinase rearrangements in melanoma and Spitz tumours.Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancersClinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.Comprehensive Characterization of Molecular Differences in Cancer between Male and Female PatientsExome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.The Conundrum of Genetic "Drivers" in Benign Conditions.NF1 Mutations Are Common in Desmoplastic Melanoma.Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations.Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.Chemotherapy Resistance Mechanisms in Advanced Skin Cancer.Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.Copy number variation in archival melanoma biopsies versus benign melanocytic lesions.Trametinib in the treatment of melanoma.Melanoma: Advances in Targeted Therapy and Molecular Markers.The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.
P2860
Q54606435-8C14DCDD-B408-422B-979A-22A2AEADA5B9Q54903981-27B27AC7-4EBA-4C96-9090-8C8645F7000EQ54953753-F3695FAA-55D9-4F8C-B78E-E14958EF03B4Q54953756-8C1BF63A-AA32-473C-94A3-F546BF88A025Q54953761-90967FB9-C1E7-4667-8C84-4ED03CB8F028Q54953764-DE9E7F1F-A64F-4B47-92A1-D6C565E24E44Q54953769-5D58D18A-F3F5-4DEB-89ED-6CBC02C02D2FQ54953770-C84A9F68-33E4-4E70-8C33-11EC6BBCF344Q54953772-B71DFC52-8BAB-4F1C-AF14-33C3E08C82D9Q54953776-AD23A768-8A4B-4E6A-953E-48E6169F1CDDQ54953780-1C97ACA5-C34D-4849-85C9-88D87D7CFABFQ54953782-C58FE17D-F68D-4789-90A4-0119A66807F8Q54953784-479B1099-5CE2-4959-B436-5285B8998C75Q54953785-E854B71D-3484-44CD-A8DA-9813B40E553DQ54953809-5B0E86DA-2A7E-4648-9245-5808486A241FQ54953813-72773B38-AB6C-498D-8E18-EC1FAE2888A5Q54953814-2DA113D5-9B63-4701-987E-75095E219DA7Q54953816-41927B2A-128B-4FE6-A9F8-CCE27B7BA8DFQ54953819-8CB4F605-B6AF-4FD3-B82C-16FDF6FE29DCQ54953833-2F4FCAA8-E5D4-47F5-B3CD-DDF336D7201CQ54953834-AC45C990-142A-4304-B0DF-A10405998862Q54953835-DB622B70-E056-42E1-B323-59B965FD0630Q54953840-547F7D73-EE24-44F7-AC98-C78B611FEFD4Q54953844-622F30D9-59EE-483C-99DD-1AEBA208DE57Q54953858-54DBE654-287E-4518-ADEF-1A49B0F8769CQ54953860-AE1D605E-CD3C-4496-9036-587DBBA84079Q54953862-5A055225-AF64-4D18-8843-041B2F57A181Q54953864-9927BAA8-E440-4C11-A027-E005169141FBQ54953868-A883B5D9-831C-4B09-A001-C52BA5118B5DQ54953888-76359F6E-1C35-463D-9098-320B61374410Q54953889-61F24924-F036-4711-BE9E-EB9F6D842B63Q54953890-984B75AD-B1EE-4FCA-A776-0FFD52C5F7E3Q54953892-83C2DF7C-8241-41B2-B1DB-3E143DF09B37Q54953893-70839988-CF0A-4DC8-A446-05C59D838F1AQ54953894-B0953EF4-37DA-4B17-BD0D-DFD18EF0BCDDQ54953896-C2D1073D-0D44-41A8-B124-A36C04FE1F05Q54953897-216B8A9A-FF89-49B9-9447-D423A7D858FFQ54953899-24AEC934-D92C-4C8E-B532-7DA233336988Q54953900-D456B992-2F0B-4495-8786-A3B3C41BB6E6Q54953901-6E26C52C-0F1E-42A9-A4FD-FE6B89ADFD3E
P1343
Q26771192-8A0B3059-79D9-4FB5-85F6-BEAB687B787CQ26795735-AFC06CD7-5A95-4BFB-8D11-A7C9D1EA0D90Q26822717-AB199017-3A08-41E2-8A50-FDDFBD51DAC8Q27003534-DAE3F540-063E-4B27-886B-0C92802C9ED4Q27006853-EDDF3DBA-65CA-45CE-AF62-AD51B3EC56E3Q27007866-E5D0C4D1-0B08-4C40-BE5B-AC99F577A10CQ27612411-9B986EDB-1DF7-45A6-85EF-E13EB572C0D4Q27853021-31BFD2B8-3884-4A77-A9ED-00B042994F22Q28079202-BB008610-AC7A-49E2-962E-55B31976FD1EQ28817145-AB51DB76-CE96-45F9-8D4A-F7DC473302C0Q30313298-CC11FCD8-2719-4EAA-8F1D-3227F50B88E9Q33578398-8A60F35D-9DE9-487D-AB5E-EEA52F553038Q33677392-D67EF132-DBD3-45A9-A2BB-68FF6890B84DQ33823452-D0ABCDBA-A3DC-46A2-94BC-F6703C2F4FD3Q34104135-FC3BC509-5777-47CC-A516-85FC3F14B718Q34430736-689E983B-6AE6-4B81-A9BE-48BC263DB707Q34667825-6F19435D-90F1-4A31-B728-5712E32EA5F4Q34670776-161FD56A-B988-4313-ABBF-FF5E200BD811Q34786402-94CDE6B4-A761-4A3C-8540-A22117C636AEQ35043887-30A15E27-A9BB-41E1-82C6-820B7DEADDACQ35658282-4DB0DA01-9772-461B-9544-6CC927327C7DQ35889525-C2233D4B-C89B-42A9-9032-F26122B5D669Q35963400-FD335894-C48D-41D6-AA0C-C71A3529B2D3Q36021891-D8971299-20DD-4AA2-8355-3EDBD623BF5DQ36232159-EC3007BD-CC74-42A1-A65B-44C0C98880D2Q36525647-8A6137E8-6323-4AAB-94B8-70B3461029D7Q36895507-35889C99-F8E2-413A-B6A6-97F1B9F939EEQ37028299-7EF6EF0F-5C5D-4ABE-ABD7-9B651A42D681Q37113976-F08CA6D9-60DA-46F3-934E-E3E1E4BD4FEAQ37245787-C78FAF5E-8FD2-455D-A7C0-3341D15764DBQ37286915-295AC855-A45D-429B-9CB6-E06EB43A3BA0Q37327493-4EC35E5C-52B0-4796-8291-71E85CEE8D2DQ37455251-E7464D55-0982-4C9F-BF13-C6540E712784Q37736532-11E6583D-C5B9-4246-8BEF-8F0811338480Q38371672-F59F86D9-0AF5-480B-89B2-2D9C4EFAAFDDQ38381518-FA396DA8-ACC7-400A-815B-E6390A8B57D2Q38392273-27641951-8BA2-43DF-9D86-FFE2A6D365CEQ38557217-8214024B-AF76-47D0-8ED4-A354D26ED5F4Q38620826-DA2BA406-6B18-40D3-BF7F-0D8AB81DD76EQ38689912-15C47BC4-5FBC-410E-967C-84EDEE0B41E6
P2860
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
@ast
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
@en
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
@nl
type
label
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
@ast
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
@en
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
@nl
altLabel
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
@en
prefLabel
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
@ast
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
@en
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
@nl
P2093
P2860
P4510
P3181
P1433
P1476
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
@en
P2093
Alexis M Jones
Aphrothiti J Hanrahan
Barry S Taylor
Cailian Liu
Christine A Pratilas
David B Solit
Michael F Berger
Moriah H Nissan
P2860
P304
P3181
P356
10.1158/0008-5472.CAN-13-2625
P407
P577
2014-04-15T00:00:00Z